M&A Deal Summary |
|
|---|---|
| Date | 2025-01-08 |
| Target | OXB - Parkinson s IP Patent Portfolio |
| Sector | Life Science |
| Buyer(s) | BlackfinBio |
| Sellers(s) | Oxford Biomedica |
| Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
BlackfinBio is a clinical gene therapy company focused on the development of treatments for rare neurological diseases. The pipeline comprises BFB-101, an IND stage AP4B1 replacement AAV gene therapy for Hereditary Spastic Paraplegia, sub-type 47 - an ultra-rare genetic neurological disease for which no treatment currently exists. BlackfinBio is based in Sheffield, United Kingdom
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (United Kingdom) | 1 of 1 |
| Year (2025) | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1995 |
| Sector | Life Science |
| Employees | 703 |
| Revenue | 90M GBP (2023) |
Oxford Biomedica is a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno associated virus, adenoviral vectors, and other viral vector types. Oxford Biomedica was founded in 1995 and is based in Oxford, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (United Kingdom) | 1 of 1 |
| Year (2025) | 1 of 1 |
